MedTrace Logo

Phase I Study of Marizomib + Panobinostat for Children With DIPG

NCT04341311 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2024-02-15

No results posted yet for this study

Summary

This research study is evaluating the safety, tolerability and preliminary efficacy of the drugs marizomib and panobinostat in pediatric patients with diffuse intrinsic pontine glioma (DIPG).

The names of the study drugs involved in this study are:

* Marizomib
* Panobinostat

Conditions

  • Diffuse Intrinsic Pontine Glioma
  • Pediatric Brainstem Glioma
  • Pediatric Brainstem Gliosarcoma, Recurrent
  • Pediatric Cancer
  • Pediatric Brain Tumor
  • Diffuse Glioma

Interventions

DRUG

Marizomib

\- Intravenously initially given every other week over a 28 day course but will go to weekly x 3 and weekly x 4 as the dose levels increase Up to 26 courses.

DRUG

Panobinostat

\- Panobinostat: Oral dosage is given 3 times weekly, every other week over a 28 day course

Sponsors & Collaborators

Principal Investigators

  • Katherine Warren, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-10
Primary Completion
2024-02-14
Completion
2024-02-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04341311 on ClinicalTrials.gov